Mon Dec 5 2022 - 08:14
Fusion Antibodies, the Belfast-based contract research firm, made a loss of £1.1 million for the six months to the end of September as it attempts to restructure the business. The company’s latest half-year results show group revenue also fell to £1.9 million, down from £2.4 million for the same period last year, while spending on research and development rose by 7 per cent to £450,000.“We are re-positioning the company’s service offering to best serve our clients in therapeutic antibody drug discovery.”
“Following the restructuring of our commercial team and once again attending in-person conferences this is the right time to re-align our services with client needs,” he said.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: